The management of multiple sclerosis patients with persistent disease activity under alemtuzumab treatment is not established yet. Concerns have been raised on the safety of autologous haematopoietic stem cell transplantation (aHSCT) after alemtuzumab treatment because of the risk of serious infectious adverse events. We report short-term safety and efficacy data from three patients treated with aHSCT following alemtuzumab treatment. Early adverse events were consistent with expected transplant toxicities. All patients were free of disease activity at the last follow-up. Our data suggest that aHSCT can be considered as a rescue treatment strategy for MS patients with persistent disease activity during alemtuzumab treatment.

中文翻译：

---

阿仑单抗治疗侵袭性多发性硬化后自体造血干细胞移植三例报告

尚未确定在阿仑单抗治疗下对具有持续疾病活动性的多发性硬化患者的管理。由于存在严重感染性不良事件的风险，阿仑单抗治疗后自体造血干细胞移植 (aHSCT) 的安全性受到关注。我们报告了阿仑单抗治疗后接受 aHSCT 治疗的三名患者的短期安全性和有效性数据。早期不良事件与预期的移植毒性一致。所有患者在最后一次随访时均无疾病活动。我们的数据表明，aHSCT 可被视为在阿仑单抗治疗期间具有持续疾病活动性的 MS 患者的抢救治疗策略。